Emma Höglund has been appointed as the new Chief Executive Officer (CEO) of Neobiomics, starting her position on April 15, 2024. Stefan Johansson, co-founder and current CEO, will take on a new position as Chief Medical Officer (CMO). Emma Höglund brings more than 15 years… Read More »Emma Höglund has been appointed as the new CEO of Neobiomics
NeoMega36® is the most recent product launched by Neobiomics. It is a Food for Special Medical Purposes, with a nutritional content tailored for preterm infants. It contains Arachidonic acid (ARA) and Docosahexaenoic acid (DHA) which are omega fatty acids, essential for infants. With the product’s… Read More »NeoMega36® launch
Neobiomics is delighted to announce the availability of ProPrems® in Mozambique. We are thrilled to expand our reach and make ProPrems® accessible to a wider audience. As soon as the interest in ProPrems® emerged in Mozambique, our dedicated team promptly commenced their efforts. We are… Read More »ProPrems® Avaliable in Mozambique
As the end of the year approaches, our company eagerly anticipates our annual Swedish “Julbord” (Christmas dinner)—an event that goes beyond festive revelry. It’s been a tradition in the company for the past three years and it’s a wonderful time to reflect on what we… Read More »Christmas Dinner to Conclude the Year
Team Neobiomics was thrilled to be participating in a conference in Italy, for the third time! Neobiomics was exhibited at the SIN 2023: 29th Congress of Italian Neonatology Society in Naples and was represented by Dr. Stefan Johansson, CEO and Founder of Neobiomics, and Carla… Read More »Team Neobiomics at the Italian National Conference of Neonatology (SIN) in Naples